SYS-CON MEDIA Authors: Yeshim Deniz, Michael Bushong, Eric Brown, Gilad Parann-Nissany, Kevin Benedict

News Feed Item

China Influenza Vaccine Industry Report 2014

DUBLIN, March 20, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/n8dfqv/china_influenza) has announced the addition of the "China Influenza Vaccine Industry Report 2014" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The China Influenza Vaccine Industry Report 2014 is a professional and in-depth study on the current state of the influenza vaccine industry in China.

The report provides a basic overview of the industry including definitions, classifications, inoculation, industry chain structure and development prospects. Influenza vaccine manufacturing technology and processes are discussed looking at equipment, process problems and technology. Production, demand, cost, price, production value and gross margin statistics are also provided.

A key feature of the report is its focus on 16 industry players providing information such as capacity production, cost, price, production value, profit margins and other relevant data. Next the feasibility of a new 8 Million Pieces/year influenza vaccine investment project is assessed. Finally the report offers overall research conclusions offered.

With 154 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.


Key Topics Covered:

Chapter One Influenza Vaccine Industry Overview

Chapter Two Influenza Vaccine Manufacturing Technology and Process

Chapter Three Influenza Vaccine Production Supply Sales Demand Market Status and Forecast

Chapter Four Influenza Vaccine Key Manufacturers

Chapter Five China 8Million Pieces/Year Influenza Vaccine Project Investment Feasibility Analysis

Chapter Six Influenza Vaccine Industry Research Conclusions

Companies Mentioned:

  • Abbott (US)
  • Aleph Biomedical (Liaoning)
  • CCBIO (Jilin Changchun)
  • Changsheng (Jilin Changchun)
  • Crucell (Holland)
  • GSK (UK)
  • Hualan Bio (Henan)
  • Lanzhou Institute of Biological Products (Qinghai)
  • Neptunus Interlong (Shenzhen)
  • Novartis (Switzerland)
  • SIOBP (Shanghai)
  • Sanofi-pasteur (France)
  • Sinovac (Beijing)
  • Tasly&Jenner (Tianjin)
  • Tiantan Biological (Beijing)
  • Tianyuan Bio-pharma (Zhejiang)

For more information visit http://www.researchandmarkets.com/research/n8dfqv/china_influenza


Media Contact: Laura Wood , +353-1-481-1716, [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.